I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Proponents of Ozempic microdosing claim you'll reap the drug's benefits with fewer side effects. But is taking small doses of GLP-1 agonists safe and effective for weight loss?

Leicester is the weight loss injection capital with almost 2,000 drugs prescribed each month, 6.8 times the proportion dished ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...